Evidence from preclinical studies suggests that targeting MEK has efficacy against uveal melanoma cells in vitro, which has led to three randomized controlled trials evaluating the MEK inhibitor selumetinib, either alone or in combination with chemotherapy [73, 74, 76, 79]. This evidence concerns the gene MAP2K7 and uveal melanoma.